NEW YORK, March 18, 2015 /PRNewswire/ -- This report analyzes the worldwide markets for Parenteral Nutrition in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -
Actavis, Inc.
Amanta Healthcare Ltd.
B. Braun Melsungen AG
Baxter International, Inc.
Claris Lifesciences Limited
Read the full report: http://www.reportlinker.com/p02772344-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Parenteral Nutrition - A Key Segment in Clinical Nutrition II-1
The Road Ahead II-2
US and Europe, the Largest Markets II-3
Table 1: World Parenteral Nutrition Market (2014): Percentage
Share Breakdown of Value Sales by Geographic Region/Country
(includes corresponding Graph/Chart) II-4
Table 2: World Parenteral Nutrition Market (2014-2020):
Growth Potential across Different Regional Markets (includes
corresponding Graph/Chart) II-4
The Large Markets Report Slight Slowdown in Y-O-Y Growth in 2013 II-4
Table 3: Per-Capita Healthcare Expenditure in Select Regions
(2013) (includes corresponding Graph/Chart) II-5
Table 4: Healthcare Spending as a Percentage of GDP (2012)
(includes corresponding Graph/Chart) II-6
A Concentrated Global PN Market II-6
Table 5: Global Market for Parenteral Nutrition by Leading
Players (2013): Percentage Share Breakdown of Value Sales for
B.Braun, Baxter International, Fresenius Kabi, Hospira and
Others (includes corresponding Graph/Chart) II-7
Select Parenteral Nutrition Products by Company II-7
2. MARKET TRENDS, DRIVERS & ISSUES II-9
Clinical Nutrition Vital for Combating Malnutrition during
Hospitalization II-9
Table 6: Daily Requirements for Adults (Male and Female) by
Nutrient Type II-9
Table 7: Energy Requirements by Age and Gender (includes
corresponding Graph/Chart) II-10
Table 8: Protein and Vitamin Requirements by Gender II-10
Table 9: Mineral Requirements by Gender and Mineral Type II-11
Rapidly Aging Demographics to Propel Demand for Parenteral
Nutrition II-11
Opportunity Indicators: II-13
Table 10: Global Population Statistics for the 65+ Age Group
(2013) (includes corresponding Graph/Chart) II-13
Table 11: Elderly Population (60+ Years) as a Percentage of
the Total Population (2012 & 2050) (includes corresponding
Graph/Chart) II-14
Table 12: Life Expectancy at Age 60 and 80 Years -
(2010-2015), (2020-2025) & (2045-2050) (includes
corresponding Graph/Chart) II-14
Table 13: Global Aging Population by Age Group: 1975-2050
(includes corresponding Graph/Chart) II-15
Table 14: Aging Population by Age Group in More Developed
Countries (1975-2050) (includes corresponding Graph/Chart) II-16
Table 15: Aging Population by Age Group in Less Developed
Countries (1975-2050) (includes corresponding Graph/Chart) II-17
Table 16: Aging Population by Age Group in Least Developed
Countries (1975-2050) (includes corresponding Graph/Chart) II-18
Rising Incidence of Chronic Diseases to Propel Growth of
Parenteral Nutrition Market II-18
Table 17: Global Parenteral Nutrition Market by Disease
Condition (2014): Percentage Share Breakdown of Number of
Patients for Cancer, Crohn's Disease, Ulcerative Colitis,
Motility Disorder, AIDS and Other Conditions (includes
corresponding Graph/Chart) II-19
Cancer Patients - the Highest PN Users II-19
Table 18: Worldwide Incidence of Cancer (2012, 2020 & 2030):
Number of New Cases Diagnosed (includes corresponding
Graph/Chart) II-20
Table 19: New Cancer Cases in the World by Affected Site:
2012 (in Thousands) (includes corresponding Graph/Chart) II-20
Table 20: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America & the Caribbean, and Africa (includes corresponding
Graph/Chart) II-21
Table 21: Global Cancer Incidence by Income Group: 2012 (in
Thousands) (includes corresponding Graph/Chart) II-21
Table 22: Cancer Incidence in High Income Countries by Site:
2012 (in Thousands) (includes corresponding Graph/Chart) II-22
Table 23: Cancer Incidence in Upper Middle Income Countries
by Site: 2012 (in Thousands) (includes corresponding
Graph/Chart) II-23
Table 24: Cancer Incidence in Lower Middle Income Countries
by Site: 2012 (in Thousands) (includes corresponding
Graph/Chart) II-24
Table 25: Cancer Incidence in Low Income Countries by Site:
2012 (in Thousands) (includes corresponding Graph/Chart) II-25
Table 26: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America & the Caribbean, and Africa (includes corresponding
Graph/Chart) II-26
Table 27: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung &
Bronchus, Prostate, Colorectal and Liver Cancers (includes
corresponding Graph/Chart) II-26
Table 28: Global Incidence of Common Cancers in Women
(2012): Number of New Cases Reported in Thousands for
Breast, Colorectal, Lung & Bronchus and Liver Cancers
(includes corresponding Graph/Chart) II-27
Table 29: Global Cancer Mortality in Men for Select Cancers
(2012): Number of Deaths in Thousands for Lung & Bronchus,
Liver, Colorectal and Prostate Cancers (includes
corresponding Graph/Chart) II-27
Table 30: Global Cancer Mortality in Women for Select
Cancers (2012): Number of Deaths in Thousands for Breast,
Lung & Bronchus, Colorectal and Liver (includes
corresponding Graph/Chart) II-28
Cancer Prone Sites based on Age II-28
Parenteral Nutrition: Critical for People with
Gastrointestinal Disorders II-28
Rising HIV Prevalence Provides Ample Growth Opportunities II-29
Global HIV Statistics - Opportunity Indicators for
Parenteral Nutrition II-30
Table 31: Global Prevalence of HIV Infection Region in 2013
(in Millions) (includes corresponding Graph/Chart) II-30
Table 32: Newly Infected HIV Population by Region in 2013
(in Thousands) (includes corresponding Graph/Chart) II-31
Table 33: Global HIV Related Deaths in 2013 by Region (in
Thousands) (includes corresponding Graph/Chart) II-32
Diabetes Mellitus: Another Major Chronic Condition II-32
Parental Nutrition Indicated for Diabetes Patients with Non-
functional GI Tract II-33
Global Diabetic Statistics - Opportunity Indicators II-34
Table 34: Worldwide Prevalence of Diabetes Mellitus by
Region (2014 & 2035) (includes corresponding Graph/Chart) II-34
Table 35: Ten Countries with the Highest DM Cases (2014)
(includes corresponding Graph/Chart) II-35
Table 36: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in North America and Caribbean (2014): Breakdown
by Country/Territory (in 000 People & %) II-36
Table 37: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Europe (2014): Breakdown by Country/Territory
(in 000 People & %) II-37
Table 38: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in South-East Asia (2014): Breakdown by
Country/Territory (in 000 People & %) (includes
corresponding Graph/Chart) II-38
Table 39: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Western Asia (2014): Breakdown by
Country/Territory (in 000 People & %) II-39
Table 40: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in South and Central America (2014): Breakdown
by Country/Territory (in 000 People & %) II-40
Table 41: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Middle East and North Africa (2014):
Breakdown by Country/Territory (in 000 People & %) II-41
Table 42: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Africa (2014): Breakdown by Country/Territory
(in 000 People & %) II-42
Rising Number of Premature Births Enhances Need for Parenteral
Nutrition II-43
Preterm Birth Statistics from WHO II-43
Table 43: Percentage of Preterm Births by Region: 2012
(includes corresponding Graph/Chart) II-44
Table 44: Top Ten Countries with the Highest Number of
Preterm Births (2012) (includes corresponding Graph/Chart) II-45
Table 45: Top Ten Countries with the Highest Rates of
Preterm Births (per 100 Live Births): 2012 (includes
corresponding Graph/Chart) II-45
Intravenous Therapy in Outpatient Settings to Boost Parenteral
Nutrition Market Growth II-46
Growing Demand for Home Intravenous Nutritional Therapies II-46
Rising Preference for Multi-Chamber Bags to Lower Cost of
Parenteral Nutrition Therapy II-47
Pre-mixed IV Nutrition: A Step towards Safer Medication Practices II-47
The Need for Low-Cost Solutions for Developing and Less-
Developed Markets II-48
Rising Popularity of Intravenous Vitamin C for Cancer Treatment II-48
Increasing Demand for Peripheral Intravenous Nutrition II-48
Iron Replacement Therapies - A Potential Market Segment II-49
Continuous Supply of Raw Material: Crucial for Production II-49
Rising Preference for Enteral Nutrition: A Threat to
Parenteral Nutrition Market II-49
Infection Control: A Prime Concern in IV Nutritional Therapy II-50
Limiting Medication Errors - A Key Concern II-51
3. PRODUCT OVERVIEW II-52
Intravenous Solutions - An Insight II-52
Intravenous Therapy II-52
Intravenous Solutions II-52
Tonicity and Osmolality II-53
Production of IV Solutions II-53
Types of IV Solutions II-53
Colloid Solutions II-53
Crystalloid Solutions II-53
Properties of IV Solution Type Based on Concentration II-54
Isotonic Crystalloids II-54
Hypertonic Crystalloids II-55
Hypotonic Crystalloids II-55
Commonly Used Crystalloid Solutions II-55
Saline Solution II-55
Normal Saline II-55
Half-Normal Saline II-56
Quarter-Normal Saline II-56
Hypertonic Saline II-56
Dextrose II-56
Saline with Additional Ingredients II-56
Intravenous Sugar Solution II-56
Dextrose Solutions or D5W II-56
Other Types II-57
Pre-mixed IV Solutions II-57
Large and Small Volume Intravenous Solutions II-57
Devices Used in IV Solutions Administration II-58
Types of Intravenous Access Devices II-58
Peripheral Cannula II-58
Central IV Lines II-59
Implantable Ports II-59
Tunneled Lines II-59
Peripherally Inserted Central Catheter (PICC) II-59
IV Fluid Packaging II-59
Possible Risks in Intravenous Therapy II-60
Embolism II-60
Electrolyte Imbalance II-60
Extravasation/Infiltration II-60
Phlebitis II-60
Infection II-61
Parenteral Nutrition - An Overview II-61
An Introduction II-61
Parenteral Nutrition Therapy II-62
Sources of Parenteral Solutions II-62
Routes of Administration II-62
Types of Parenteral Nutrition Solutions II-63
Total Parenteral Nutrition (TPN) II-63
Daily Requirements for Total Parenteral Nutrition (TPN) in
Adults II-64
Daily Recommended Parenteral Nutritional Intakes for Newborns II-65
Partial Parenteral Nutrition (PPN) II-66
Home Parenteral Nutrition II-66
Central and Peripheral Parenteral Nutrition II-66
Inpatient and Outpatient Environments II-66
Parenteral Nutrition Formulations II-66
Standard Solutions II-66
Three-in-One Standard Bags II-67
Two-in-one Standard Bags II-67
Individual Solutions II-67
Non-Standard Solutions II-67
Classification of Parenteral Nutrition by Type of Nutrients II-67
Amino Acids II-67
Carbohydrates II-68
Lipids II-68
Minerals & Electrolytes II-68
Micronutrients II-69
Vitamins II-69
Trace Elements II-70
Large and Small Volume Parenteral Solutions II-70
Large Volume Parenteral (LVP) Solutions II-71
Small Volume Parenteral (SVP) Solutions II-71
IV Fat Emulsions - Enabling Maintenance of Bodyweight II-71
Regulatory Prerequisites II-72
4. PRODUCT LAUNCHES II-73
Kabi Introduces Kabiven® in the US II-73
FDA Clears Fresenius Kabi for Emergency Import of
Injectionable TPN Drugs II-73
Marck Biosciences Receives MCC Approval for Pharma Products II-73
Baxter to Launch Plasma-Lyte A in India II-73
Health Robotics to Unveil i.v.STATION® 2 for TPN II-73
B. Braun Receives FDA approval for Large Volume PN Solutions II-73
Claris Receives USFDA Approval for Marketing Products in the US II-74
Taiho to Roll Out Aloxi® 0.75mg I.V Infusion Bag II-74
5. RECENT INDUSTRY ACTIVITY II-75
Aesynt™ Takes Over Health Robotics II-75
Baxter to Create New Independent Biopharmaceutical Company II-75
Hospira Recalls IV Electrolyte Solution II-75
Becton, Dickinson and Company Takes over Cato Software Solutions II-75
Baxter to Acquire Gambro AB II-75
Otsuka Pharmaceutical Factory Forms a JV with Claris
Lifesciences and Mitsui II-75
B. Braun Establishes Pharmaceutical Plant in Fogelsville, US II-76
Baxter International Completes Acquisition of SIGMA International II-76
Aperture Health Takes Over Triad Therapeutics II-76
Children's Hospitals and Clinics of Minnesota Deploys Cerner
CareAwareiBusTM of CareFusion II-76
Baxter Initiates Class I Recall of Automix Compounder II-76
6. FOCUS ON SELECT GLOBAL PLAYERS II-77
Actavis, Inc. (US) II-77
Amanta Healthcare Ltd (India) II-77
B. Braun Melsungen AG (Germany) II-77
Baxter International, Inc. (US) II-78
Claris Lifesciences Limited (India) II-79
Fresenius KABI AG (Germany) II-79
Grifols International S.A. (Spain) II-80
Hospira, Inc. (US) II-81
Otsuka Pharmaceutical Factory, Inc. (Japan) II-81
Sichuan Kelun Pharmaceutical Co., Ltd. (China) II-82
Sino-Swed Pharmaceutical Corp. Ltd. (China) II-82
7. GLOBAL MARKET PERSPECTIVE II-83
Table 46: World Recent Past, Current and Future Analysis for
Parenteral Nutrition by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Middle East/Africa, and Latin America
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) II-83
Table 47: World Historic Review for Parenteral Nutrition by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Middle East/Africa, and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) II-84
Table 48: World 14-Year Perspective for Parenteral Nutrition
by Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa,
and Latin America Markets for the Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) II-85
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Rapidly Aging Demographics: A Major Driving Factor III-1
Table 49: North American Elderly Population by Age Group
(1975-2050) (includes corresponding Graph/Chart) III-2
Rising Cancer Incidence Rate Drives Demand for Parenteral
Nutrition III-3
Table 50: New Cancer Cases in the US by Gender and Affected
Site: 2014 III-4
Table 51: New Cancer Cases in Males in US by Leading Site:
2014 (includes corresponding Graph/Chart) III-5
Table 52: New Cancer Cases in Females in US by Leading
Site: 2014 (includes corresponding Graph/Chart) III-6
Table 53: New Cancer Cases in US by State: 2014 III-7
Table 54: US Cancer Incidence for All Body Sites by Gender &
Age Group (2013): New Cancer Cases for Males & Females
for the Age groups Under 65 years; and 65 years and Above
(includes corresponding Graph/Chart) III-8
Cancer Mortality Statistics III-9
Table 55: Cancer Related Deaths in the US by Gender and
Body Site: 2014 III-9
Table 56: Cancer Related Deaths in Males in US by Leading
Site: 2014 (includes corresponding Graph/Chart) III-10
Table 57: Cancer Related Deaths in Females in US by
Leading Site: 2014 (includes corresponding Graph/Chart) III-11
Table 58: Number of Deaths Related to Major Types of
Cancer in US by State: 2014 III-12
Prevalence of Diabetes Mellitus in the US - A Case for
Parenteral Nutrition III-13
Table 59: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in North America and Caribbean (2014): Breakdown
by Country/Territory (in 000 People & %) III-13
Shift towards Enteral Nutrition Therapies - A Threat to
Parenteral Nutrition Market III-14
Advantages and Disadvantages of Enteral Nutrition over
Parenteral Nutrition III-14
Medicare Coverage for Parenteral Nutrition Therapy III-14
Reimbursement Regulations to Hamper Market Growth III-15
A.S.P.E.N. Practice Guidelines for Parenteral Nutrition III-16
A.S.P.E.N. Guidelines for Parenteral Nutrition (as of 2004) III-16
Impact of Patient Protection and Affordable Care Act on IV
Solutions Market III-18
Product Launches III-18
Strategic Corporate Developments III-19
Select Players III-20
B.Market Analytics III-23
Table 60: US Recent Past, Current and Future Analysis for
Parenteral Nutrition Analyzed with Annual Sales Figures in
US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-23
Table 61: US Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-24
2. CANADA III-25
A.Market Analysis III-25
Outlook III-25
Rising Incidence of Cancer - A Business Case for Parenteral
Nutrition Market III-25
Table 62: New Cancer Cases in Canada by Gender and Affected
Site: 2014 (includes corresponding Graph/Chart) III-26
Table 63: New Cancer Cases in Canada by Province: 2014
(includes corresponding Graph/Chart) III-27
Table 64: New Cancer Cases in Canada by Age Group: 2014
(includes corresponding Graph/Chart) III-28
Table 65: Cancer Related Deaths in Canada by Gender and
Affected Site: 2014 (includes corresponding Graph/Chart) III-29
Table 66: Cancer Related Deaths in Canada by Province: 2014
(includes corresponding Graph/Chart) III-30
Table 67: Cancer Related Deaths in Canada by Age Group:
2014 (includes corresponding Graph/Chart) III-31
Diabetes Leads to Increase in GI Disorder Cases -
Opportunity for PN III-31
Table 68: Prevalence of Diabetes Mellitus in Canada: 2014 III-32
B.Market Analytics III-32
Table 69: Canadian Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-32
Table 70: Canadian Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-33
3. JAPAN III-34
A.Market Analysis III-34
Rising Cancer and Diabetes Cases Provide Growth Opportunity III-34
Table 71: Cancer Related Deaths by Age Groups: 2013
(includes corresponding Graph/Chart) III-34
Table 72: Prevalence of Diabetes Mellitus in Japan (2014) III-35
Product Launch III-35
Otsuka Pharmaceutical Factory, Inc. - A Major Player III-35
B.Market Analytics III-36
Table 73: Japanese Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-36
Table 74: Japanese Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-37
4. EUROPE III-38
A.Market Analysis III-38
Outlook III-38
Aging Population & Rising Incidence of Chronic Diseases to
Drive Growth III-38
Aging Statistics III-39
Table 75: Population Breakup by Age Group for Select
European Countries: 2012 (as a Percentage of Total
Population) (includes corresponding Graph/Chart) III-39
Cancer and Diabetes Mellitus in Europe: Key Statistics III-40
Table 76: European Predicted Cancer Deaths in 2014: Number
of Deaths by Gender and Major Cancer Type (includes
corresponding Graph/Chart) III-40
Table 77: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Europe by Country/Territory (2014) (In 000
People & %) III-41
B.Market Analytics III-42
Table 78: European Recent Past, Current and Future Analysis
for Parenteral Nutrition by Geographic Region - France,
Germany, Italy, UK, Spain, Russia, and Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-42
Table 79: European Historic Review for Parenteral Nutrition
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia, and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for the Years 2007
through 2013 (includes corresponding Graph/Chart) III-43
Table 80: European 14-Year Perspective for Parenteral
Nutrition by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia,
and Rest of Europe Markets for the Years 2007, 2015 and 2020
(includes corresponding Graph/Chart) III-44
4a. FRANCE III-45
Market Analysis III-45
Table 81: French Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-45
Table 82: French Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-46
4b. GERMANY III-47
A.Market Analysis III-47
Outlook III-47
Select Players III-47
B.Market Analytics III-49
Table 83: German Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-49
Table 84: German Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-50
4c. ITALY III-51
A.Market Analysis III-51
Product Launch III-51
B.Market Analytics III-51
Table 85: Italian Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-51
Table 86: Italian Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-52
4d. THE UNITED KINGDOM III-53
Market Analysis III-53
Table 87: UK Recent Past, Current and Future Analysis for
Parenteral Nutrition Analyzed with Annual Sales Figures in
US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-53
Table 88: UK Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-54
4e. SPAIN III-55
A.Market Analysis III-55
Outlook III-55
Grifols International S.A. - A Key Player III-55
B.Market Analytics III-56
Table 89: Spanish Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-56
Table 90: Spanish Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-57
4f. RUSSIA III-58
Market Analysis III-58
Table 91: Russian Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-58
Table 92: Russian Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-59
4G. REST OF EUROPE III-60
A.Market Analysis III-60
Strategic Corporate Developments III-60
B.Market Analytics III-61
Table 93: Rest of European Recent Past, Current and Future
Analysis for Parenteral Nutrition Analyzed with Annual Sales
Figures in US$ Million for the Years 2014 through 2020
(includes corresponding Graph/Chart) III-61
Table 94: Rest of European Historic Review for Parenteral
Nutrition Analyzed with Annual Sales Figures in US$ Million
for the Years 2007 through 2013 (includes corresponding
Graph/Chart) III-62
5. ASIA-PACIFIC III-63
A.Market Analysis III-63
Outlook III-63
Diabetes and HIV Statistics in Asia-Pacific III-63
Table 95: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Southeast Asia (2014): Breakdown by
Country/Territory (in 000 People & %) (includes
corresponding Graph/Chart) III-63
Table 96: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Western Asia by Country/Territory (2014) (In
000s & %) III-64
Table 97: Incidence of Type 1 Diabetes in Children by
Select Countries in Western Pacific (2012) (includes
corresponding Graph/Chart) III-65
Table 98: Top 12 Countries in Asia-Pacific with Highest HIV
Incidence (2012) (includes corresponding Graph/Chart) III-65
B.Market Analytics III-66
Table 99: Asia-Pacific Recent Past, Current and Future
Analysis for Parenteral Nutrition by Geographic Region -
Australia, China and Rest of Asia-Pacific Markets
Independently Analyzed with Annual Sales Figures in US$
Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-66
Table 100: Asia-Pacific Historic Review for Parenteral
Nutrition by Geographic Region - Australia, China and Rest
of Asia-Pacific Markets Independently Analyzed with Annual
Sales Figures in US$ Million for the Years 2007 through 2013
(includes corresponding Graph/Chart) III-67
Table 101: Asia-Pacific 14-Year Perspective for Parenteral
Nutrition by Geographic Region - Percentage Breakdown of
Value Sales for Australia, China and Rest of Asia-Pacific
Markets for the Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) III-68
5a. AUSTRALIA III-69
Market Analysis III-69
Table 102: Australian Recent Past, Current and Future
Analysis for Parenteral Nutrition Analyzed with Annual Sales
Figures in US$ Million for the Years 2014 through 2020
(includes corresponding Graph/Chart) III-69
Table 103: Australian Historic Review for Parenteral
Nutrition Analyzed with Annual Sales Figures in US$ Million
for the Years 2007 through 2013 (includes corresponding
Graph/Chart) III-70
5b. CHINA III-71
A.Market Analysis III-71
Outlook III-71
Select Players III-71
B.Market Analytics III-72
Table 104: Chinese Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-72
Table 105: Chinese Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-73
5c. INDIA III-74
A.Market Analysis III-74
Outlook III-74
Strategic Corporate Developments III-74
Select Players III-74
B.Market Analytics III-76
Table 106: India Recent Past, Current and Future Analysis
for Parenteral Nutrition Analyzed with Annual Sales Figures
in US$ Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-76
Table 107: India Historic Review for Parenteral Nutrition
Analyzed with Annual Sales Figures in US$ Million for the
Years 2007 through 2013 (includes corresponding Graph/Chart) III-77
5d. REST OF ASIA-PACIFIC III-78
Market Analysis III-78
Table 108: Rest of Asia-Pacific Recent Past, Current and
Future Analysis for Parenteral Nutrition Analyzed with
Annual Sales Figures in US$ Million for the Years 2014
through 2020 (includes corresponding Graph/Chart) III-78
Table 109: Rest of Asia-Pacific Historic Review for
Parenteral Nutrition Analyzed with Annual Sales Figures in
US$ Million for the Years 2007 through 2013 (includes
corresponding Graph/Chart) III-79
6. MIDDLE EAST/AFRICA III-80
A.Market Analysis III-80
Increasing Incidence of Chronic Conditions: Opportunity for
PN Market III-80
Diabetes Prevalence Statistics III-81
Table 110: Prevalence of Diabetes Mellitus among 20-79 Yrs
Age Group in Africa (2014): Breakdown by Country/Territory
(in 000 People & %) III-81
Table 111: Prevalence of Diabetes Mellitus in Middle East &
North Africa (2014): Breakdown by Country/Territory and Age
Group (in 000 People & %) (includes corresponding
Graph/Chart) III-82
Product Launch III-83
B.Market Analytics III-83
Table 112: Middle East/Africa Recent Past, Current and
Future Analysis for Parenteral Nutrition Analyzed with
Annual Sales Figures in US$ Million for the Years 2014
through 2020 (includes corresponding Graph/Chart) III-83
Table 113: Middle East/Africa Historic Review for Parenteral
Nutrition Analyzed with Annual Sales Figures in US$ Million
for the Years 2007 through 2013 (includes corresponding
Graph/Chart) III-84
7. LATIN AMERICA III-85
A.Market Analysis III-85
Outlook III-85
Rising Incidence of Diabetes in Latin America - Opportunity
Indicator III-85
Table 114: Prevalence of Diabetes Mellitus in South &
Central America (2013 & 2035): Breakdown by Country and Age
Group (In 000 People & %) III-86
B.Market Analytics III-87
Table 115: Latin America Recent Past, Current and Future
Analysis for Parenteral Nutrition by Geographic Region -
Brazil, Mexico and Rest of Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for the Years 2014 through 2020 (includes
corresponding Graph/Chart) III-87
Table 116: Latin America Historic Review for Parenteral
Nutrition by Geographic Region - Brazil, Mexico and Rest of
Latin America Markets Independently Analyzed with Annual
Sales Figures in US$ Million for the Years 2007 through 2013
(includes corresponding Graph/Chart) III-88
Table 117: Latin America 14-Year Perspective for Parenteral
Nutrition by Geographic Region - Percentage Breakdown of
Value Sales for Brazil, Mexico and Rest of Latin America
Markets for the Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) III-89
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 25 (including Divisions/Subsidiaries - 31)
The United States (8)
Japan (3)
Europe (11)
- France (1)
- Germany (3)
- The United Kingdom (1)
- Italy (1)
- Spain (1)
- Rest of Europe (4)
Asia-Pacific (Excluding Japan) (8)
Africa (1)
Read the full report: http://www.reportlinker.com/p02772344-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article